Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
RECRUITING
Total Enrollment
1000 participants
Study Classification
OBSERVATIONAL
Study Start Date
2021-12-30
Study Completion Date
2029-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Primary sclerosing cholangitis (PSC) is a rare liver disease that damages the liver's bile ducts. Bile ducts are tiny tubes that carry bile from the liver to the small intestine. Bile is a liquid produced by the liver that helps us absorb and use the nutrients in the food we eat. In people with PSC, the bile backs up into the liver and will damage it, causing scarring of the liver.
The purposes of this study are to:
* Collect medical and other data to learn more about PSC, how it progresses, and identify factors that may cause the disease to progress more quickly.
* Ask questions about how PSC symptoms affect your child's life to learn more about its impact on your child's daily functioning
* Children with PSC who are seen at one of the participating clinical sites in the Childhood Liver Disease Research Network (ChiLDReN) will be asked to contribute information, DNA, and other specimens. The information and specimens will be available to investigators to carry out approved research aimed at learning more about the possible causes and long-term effects of PSC.
The purposes of this study are to:
* Collect medical and other data to learn more about PSC, how it progresses, and identify factors that may cause the disease to progress more quickly.
* Ask questions about how PSC symptoms affect your child's life to learn more about its impact on your child's daily functioning
* Children with PSC who are seen at one of the participating clinical sites in the Childhood Liver Disease Research Network (ChiLDReN) will be asked to contribute information, DNA, and other specimens. The information and specimens will be available to investigators to carry out approved research aimed at learning more about the possible causes and long-term effects of PSC.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Assess Safety and Effectiveness of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis.
NCT05627362
Primary Sclerosing Cholangitis
ACTIVE_NOT_RECRUITING
PHASE2
A Study of HTD1801 in Adolescents With Primary Sclerosing Cholangitis (PSC)
NCT03678480
Primary Sclerosing Cholangitis
Cholangitis
Cholangitis, Sclerosing
+4 more
WITHDRAWN
PHASE2
NPD Measurements in PSC Patients
NCT00476814
Primary Sclerosing Cholangitis
UNKNOWN
Stem Cell Transplantation in Patients With Primary Biliary Cirrhosis
NCT00393185
Primary Biliary Cirrhosis
WITHDRAWN
PHASE1
Colangioids to Define the Genetic Factors Involved in Atypical Primary Sclerosing Cholangitis
NCT06865924
PSC
ACTIVE_NOT_RECRUITING
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Pediatric primary sclerosing cholangitis (PSC) is a rare autoimmune biliary fibrosing disease that leads to significant morbidity, the need for liver transplantation in \~50% of patients, and an increased risk for biliary and colorectal cancers in adulthood. The progression of the biliary disease in children is variable and risk factors associated with a more rapid progression of disease have not been adequately studied. Importantly, pediatric hepatologists have never previously collaborated with inflammatory bowel disease (IBD) specialists to rigorously explore interactions between colonic inflammation and liver disease. New non-invasive imaging modalities to measure fibrosis have not been explored in pediatric PSC. Furthermore, the impact that PSC has on the global functioning of children is not well understood, and likely underappreciated.
The natural history of pediatric PSC is poorly understood. This study aims to determine risk factors, including activity of co-existent IBD, associated with more rapid progression of disease, characterize the impact of PSC on global functioning, define the spectrum and prognostic value of biliary tract disease and liver fibrosis based on novel imaging techniques, and establish a biobank of specimens for future mechanistic studies aimed at discovering biomarkers pertaining to etiology and severity of PSC and novel mechanisms of immunopathogenesis of disease. This comprehensive observational and longitudinal study will delineate unique aspects of the natural history and severity of pediatric PSC and of associated IBD and provide necessary data for future therapeutic trials. It aims to provide a platform to discover and validate circulating and imaging biomarkers, which may serve as surrogate endpoints in future interventional studies.
The natural history of pediatric PSC is poorly understood. This study aims to determine risk factors, including activity of co-existent IBD, associated with more rapid progression of disease, characterize the impact of PSC on global functioning, define the spectrum and prognostic value of biliary tract disease and liver fibrosis based on novel imaging techniques, and establish a biobank of specimens for future mechanistic studies aimed at discovering biomarkers pertaining to etiology and severity of PSC and novel mechanisms of immunopathogenesis of disease. This comprehensive observational and longitudinal study will delineate unique aspects of the natural history and severity of pediatric PSC and of associated IBD and provide necessary data for future therapeutic trials. It aims to provide a platform to discover and validate circulating and imaging biomarkers, which may serve as surrogate endpoints in future interventional studies.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Primary Sclerosing Cholangitis
Liver Diseases
Cholangitis, Sclerosing
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Observational Model Type
COHORT
Study Time Perspective
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Patients with the clinical diagnosis of large or small duct PSC made at any time prior to enrollment are screened for eligibility to participate in this prospective cohort study. The site PI will determine eligibility following review of MRCP or ERCP images with the site radiologist to confirm presence of an abnormal cholangiogram at the time of diagnosis of large duct PSC. Liver histopathology obtained at the time of diagnosis of small duct PSC will be reviewed with the site pathologist prior to enrollment.
1. Aged 2 through 25 years at time of screening.
2. Diagnosis of large duct PSC based on review of cholangiogram by MRC, ERC, or intraoperative cholangiogram (IOC) by the site radiologist and interpreted to be consistent with PSC, based on one or more of the following:
* Focal structuring of the bile duct(s)
* Dominant stricture of the common bile duct
* Saccular dilatation of bile duct(s)
* Beaded appearance of bile duct(s)
* Pruning appearance of the distal bile duct branches
AND/OR
3. Diagnosis of small duct PSC based on review of liver histopathology by the site pathologist and interpreted to be compatible with PSC:
* Probable small duct PSC: biopsy with ≥3 of 5 criteria: periductal edema, concentric inflammation, bile duct injury, ductular reaction, and neutrophils in bile ducts (cholangitis) OR...
* Definitive small duct PSC: Periductal fibrosis/ "onion skinning" around interlobular bile ducts or smaller profiles
4. Stated willingness to comply with all study procedures and availability for the duration of the study.
5. Able to provide informed consent/assent
Participants for the imaging study are eligible if they are:
1. Aged 8 through 25 years at the time of screening
2. No absolute contraindication to MRI
3. No skin condition that could be aggravated by MREL
4. Meet all other eligibility criteria of the PSC Observational Study
1. Aged 2 through 25 years at time of screening.
2. Diagnosis of large duct PSC based on review of cholangiogram by MRC, ERC, or intraoperative cholangiogram (IOC) by the site radiologist and interpreted to be consistent with PSC, based on one or more of the following:
* Focal structuring of the bile duct(s)
* Dominant stricture of the common bile duct
* Saccular dilatation of bile duct(s)
* Beaded appearance of bile duct(s)
* Pruning appearance of the distal bile duct branches
AND/OR
3. Diagnosis of small duct PSC based on review of liver histopathology by the site pathologist and interpreted to be compatible with PSC:
* Probable small duct PSC: biopsy with ≥3 of 5 criteria: periductal edema, concentric inflammation, bile duct injury, ductular reaction, and neutrophils in bile ducts (cholangitis) OR...
* Definitive small duct PSC: Periductal fibrosis/ "onion skinning" around interlobular bile ducts or smaller profiles
4. Stated willingness to comply with all study procedures and availability for the duration of the study.
5. Able to provide informed consent/assent
Participants for the imaging study are eligible if they are:
1. Aged 8 through 25 years at the time of screening
2. No absolute contraindication to MRI
3. No skin condition that could be aggravated by MREL
4. Meet all other eligibility criteria of the PSC Observational Study
Exclusion Criteria
An individual who meets any of the following criteria at baseline will be excluded from participation in this study.
1. History of liver transplantation
2. History bone marrow transplantation
3. History of primary or acquired immunodeficiency predisposing to secondary sclerosing cholangitis, for instance: hyper-IgM syndrome, severe combined immunodeficiency (SCID) syndrome, common variable immunodeficiency (CVID) syndrome, cartilage hair hypoplasia syndrome, or HIV/AIDS
4. History of histiocytosis, including Langerhans cell histiocytosis (LCH), or hemophagocytic lymphohistiocytosis (HLH)
5. History of ischemic cholangitis
6. History of portal vein thrombosis with biliopathy, veno-occlusive disease, or abdominal radiation vasculopathy
7. History of recurrent pyogenic cholangitis
8. History of biliary tract surgery for cholecystolithiasis prior to cholangiogram/liver biopsy evaluated to determine enrollment
9. History of biliary tract surgery for choledochal cyst
10. History of hepatocellular carcinoma, or hepatoblastoma
11. History of surgical biliary trauma
12. History of congenital cytomegalovirus (CMV) hepatitis
13. History of Sickle Cell Disease
14. History of cystic fibrosis, biliary atresia, Caroli disease/congenital hepatic fibrosis, or progressive familial intrahepatic cholestasis type 3/MDR3 disease
15. History of cardiac hepatopathy.
16. History of metabolic disorders, including Wilson's disease, glycogen storage disorder, Alpha-1 Antitrypsin deficiency
17. Diagnosis of systemic lupus erythematosus (SLE)
18. Concurrent pregnancy at the time of enrollment -
1. History of liver transplantation
2. History bone marrow transplantation
3. History of primary or acquired immunodeficiency predisposing to secondary sclerosing cholangitis, for instance: hyper-IgM syndrome, severe combined immunodeficiency (SCID) syndrome, common variable immunodeficiency (CVID) syndrome, cartilage hair hypoplasia syndrome, or HIV/AIDS
4. History of histiocytosis, including Langerhans cell histiocytosis (LCH), or hemophagocytic lymphohistiocytosis (HLH)
5. History of ischemic cholangitis
6. History of portal vein thrombosis with biliopathy, veno-occlusive disease, or abdominal radiation vasculopathy
7. History of recurrent pyogenic cholangitis
8. History of biliary tract surgery for cholecystolithiasis prior to cholangiogram/liver biopsy evaluated to determine enrollment
9. History of biliary tract surgery for choledochal cyst
10. History of hepatocellular carcinoma, or hepatoblastoma
11. History of surgical biliary trauma
12. History of congenital cytomegalovirus (CMV) hepatitis
13. History of Sickle Cell Disease
14. History of cystic fibrosis, biliary atresia, Caroli disease/congenital hepatic fibrosis, or progressive familial intrahepatic cholestasis type 3/MDR3 disease
15. History of cardiac hepatopathy.
16. History of metabolic disorders, including Wilson's disease, glycogen storage disorder, Alpha-1 Antitrypsin deficiency
17. Diagnosis of systemic lupus erythematosus (SLE)
18. Concurrent pregnancy at the time of enrollment -
Minimum Eligible Age
2 Years
Maximum Eligible Age
25 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Sponsor Role
collaborator
Arbor Research Collaborative for Health
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Cara Mack, MD
Role: STUDY_CHAIR
Medical College of Wisconsin-Milwaukee
Ed Doo, MD
Role: STUDY_DIRECTOR
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Katrina Loh, MD
Role: STUDY_DIRECTOR
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
John Magee, MD
Role: PRINCIPAL_INVESTIGATOR
University of Michigan
Lisa Henn, PhD
Role: PRINCIPAL_INVESTIGATOR
Arbor Research Collaborative for Health
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Children's Hospital of Los Angeles
Los Angeles, California, United States
Site Status
RECRUITING
Children's Hospital Colorado
Aurora, Colorado, United States
Site Status
RECRUITING
Children's Healthcare of Atlanta
Atlanta, Georgia, United States
Site Status
RECRUITING
Ann & Robert H Lurie Children's Hospital
Chicago, Illinois, United States
Site Status
RECRUITING
Riley Hospital for Children
Indianapolis, Indiana, United States
Site Status
COMPLETED
Cincinnati Children's Hospital Medical
Cincinnati, Ohio, United States
Site Status
RECRUITING
The Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States
Site Status
RECRUITING
UPMC Children's Hospital of Pittsburgh
Pittsburgh, Pennsylvania, United States
Site Status
RECRUITING
Texas Children's Hospital (Baylor College of Medicine)
Houston, Texas, United States
Site Status
RECRUITING
The University of Utah
Salt Lake City, Utah, United States
Site Status
RECRUITING
Seattle Children's Hospital
Seattle, Washington, United States
Site Status
RECRUITING
The Hospital for Sick Children
Toronto, Ontario, Canada
Site Status
COMPLETED
Countries
Review the countries where the study has at least one active or historical site.
United States
Canada
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Hirschfield GM, Karlsen TH, Lindor KD, Adams DH. Primary sclerosing cholangitis. Lancet. 2013 Nov 9;382(9904):1587-99. doi: 10.1016/S0140-6736(13)60096-3. Epub 2013 Jun 28.
Reference Type
BACKGROUND
Eaton JE, Talwalkar JA, Lazaridis KN, Gores GJ, Lindor KD. Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management. Gastroenterology. 2013 Sep;145(3):521-36. doi: 10.1053/j.gastro.2013.06.052. Epub 2013 Jul 1.
Reference Type
BACKGROUND
Bambha K, Kim WR, Talwalkar J, Torgerson H, Benson JT, Therneau TM, Loftus EV Jr, Yawn BP, Dickson ER, Melton LJ 3rd. Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. Gastroenterology. 2003 Nov;125(5):1364-9. doi: 10.1016/j.gastro.2003.07.011.
Reference Type
BACKGROUND
Deneau M, Jensen MK, Holmen J, Williams MS, Book LS, Guthery SL. Primary sclerosing cholangitis, autoimmune hepatitis, and overlap in Utah children: epidemiology and natural history. Hepatology. 2013 Oct;58(4):1392-400. doi: 10.1002/hep.26454. Epub 2013 Aug 13.
Reference Type
BACKGROUND
Toy E, Balasubramanian S, Selmi C, Li CS, Bowlus CL. The prevalence, incidence and natural history of primary sclerosing cholangitis in an ethnically diverse population. BMC Gastroenterol. 2011 Jul 18;11:83. doi: 10.1186/1471-230X-11-83.
Reference Type
BACKGROUND
Olsson R, Danielsson A, Jarnerot G, Lindstrom E, Loof L, Rolny P, Ryden BO, Tysk C, Wallerstedt S. Prevalence of primary sclerosing cholangitis in patients with ulcerative colitis. Gastroenterology. 1991 May;100(5 Pt 1):1319-23.
Reference Type
BACKGROUND
Ricciuto A, Kamath BM, Griffiths AM. The IBD and PSC Phenotypes of PSC-IBD. Curr Gastroenterol Rep. 2018 Mar 28;20(4):16. doi: 10.1007/s11894-018-0620-2.
Reference Type
BACKGROUND
Mieli-Vergani G, Vergani D, Baumann U, Czubkowski P, Debray D, Dezsofi A, Fischler B, Gupte G, Hierro L, Indolfi G, Jahnel J, Smets F, Verkade HJ, Hadzic N. Diagnosis and Management of Pediatric Autoimmune Liver Disease: ESPGHAN Hepatology Committee Position Statement. J Pediatr Gastroenterol Nutr. 2018 Feb;66(2):345-360. doi: 10.1097/MPG.0000000000001801.
Reference Type
BACKGROUND
Debray D, Pariente D, Urvoas E, Hadchouel M, Bernard O. Sclerosing cholangitis in children. J Pediatr. 1994 Jan;124(1):49-56. doi: 10.1016/s0022-3476(94)70253-5.
Reference Type
BACKGROUND
Smolka V, Karaskova E, Tkachyk O, Aiglova K, Ehrmann J, Michalkova K, Konecny M, Volejnikova J. Long-term follow-up of children and adolescents with primary sclerosing cholangitis and autoimmune sclerosing cholangitis. Hepatobiliary Pancreat Dis Int. 2016 Aug;15(4):412-8. doi: 10.1016/s1499-3872(16)60088-7.
Reference Type
BACKGROUND
Feldstein AE, Perrault J, El-Youssif M, Lindor KD, Freese DK, Angulo P. Primary sclerosing cholangitis in children: a long-term follow-up study. Hepatology. 2003 Jul;38(1):210-7. doi: 10.1053/jhep.2003.50289.
Reference Type
BACKGROUND
Miloh T, Arnon R, Shneider B, Suchy F, Kerkar N. A retrospective single-center review of primary sclerosing cholangitis in children. Clin Gastroenterol Hepatol. 2009 Feb;7(2):239-45. doi: 10.1016/j.cgh.2008.10.019. Epub 2008 Oct 30.
Reference Type
BACKGROUND
Valentino PL, Wiggins S, Harney S, Raza R, Lee CK, Jonas MM. The Natural History of Primary Sclerosing Cholangitis in Children: A Large Single-Center Longitudinal Cohort Study. J Pediatr Gastroenterol Nutr. 2016 Dec;63(6):603-609. doi: 10.1097/MPG.0000000000001368.
Reference Type
BACKGROUND
Wilschanski M, Chait P, Wade JA, Davis L, Corey M, St Louis P, Griffiths AM, Blendis LM, Moroz SP, Scully L, et al. Primary sclerosing cholangitis in 32 children: clinical, laboratory, and radiographic features, with survival analysis. Hepatology. 1995 Nov;22(5):1415-22.
Reference Type
BACKGROUND
Related Links
Access external resources that provide additional context or updates about the study.
https://childrennetwork.org/
Childhood Liver Disease Research Network (ChiLDReN) website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PSC Study - ChiLDReN Network
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Open-Label Study of HTD1801 in Adult Subjects With Primary Biliary Cholangitis
NCT04604652
COMPLETED
PHASE2
Development of a Patient-Reported Outcome Measure to Assess Symptoms in Patients With Primary Sclerosing Cholangitis (PSC)
NCT02247934
COMPLETED
Mitomycin C Therapy for Patients With Primary Sclerosing Cholangitis
NCT01688024
UNKNOWN
PHASE2
A Study Observing Everyday Effectiveness and Safety of the Drug Elafibranor in Participants With Primary Biliary Cholangitis Who Are Receiving Ongoing Treatment
NCT06447168
RECRUITING
A POC and Dose-Ranging Study of HTD1801 in PSC Patients
NCT03333928
COMPLETED
PHASE2
A 5-year Longitudinal Observational Study of Patients With Primary Biliary Cholangitis
NCT02932449
COMPLETED
Umbilical Cord Mesenchymal Stem Cells in Primary Sclerosing Cholangitis
NCT03516006
UNKNOWN
PHASE1/PHASE2
Pentoxifylline for Primary Biliary Cirrhosis
NCT01249092
COMPLETED
PHASE2
Statin Therapy in Primary Sclerosing Cholangitis (PSC): a Multi-omics Study
NCT05912387
RECRUITING
EARLY_PHASE1
Pilot Study of Budesonide for Patients With Primary Sclerosing Cholangitis
NCT00004842
COMPLETED
PHASE1
Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC)
NCT04526665
ACTIVE_NOT_RECRUITING
PHASE3
Evaluation of the Safety and Efficacy of HK-660S in Patients With Primary Sclerosing Cholangitis
NCT05866809
COMPLETED
PHASE2
A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis
NCT06016842
RECRUITING
PHASE3
A Study of TAK-781 in Healthy Volunteers and in Participants With Non-Cirrhotic Primary Sclerosing Cholangitis (PSC)
NCT07229911
NOT_YET_RECRUITING
PHASE1
Effect and Safety of Oral Vancomycin in Primary Sclerosing Cholangitis Patients
NCT02605213
UNKNOWN
PHASE4
A Study to Evaluate the Safety, and Tolerability, and Efficacy of Seladelpar in Patients With PSC
NCT04024813
TERMINATED
PHASE2
Sulfasalazine for the Treatment of Primary Sclerosing Cholangitis
NCT03561584
RECRUITING
PHASE2
Mesenchymal Stem Cell Transplantation for Refractory Primary Biliary Cholangitis
NCT03668145
UNKNOWN
NA
Global Prospective, Observational Cohort of Adult Patients With Primary Sclerosing Cholangitis (WIND-PSC Study)
NCT06297993
RECRUITING
Efficacy of 24 Month of Bezafibrate in Primary Sclerosing Cholangitis With Persistent Cholestasis Despite Ursodeoxycholic Acid Therapy
NCT04309773
UNKNOWN
PHASE3
Efficacy and Safety of HK-660S in the Treatment of Primary Sclerosing Cholangitis
NCT06975150
NOT_YET_RECRUITING
PHASE2
Pilot Study of FFP104 Dose Escalation in PBC Subjects
NCT02193360
UNKNOWN
PHASE1/PHASE2
Pharmacologic Approaches to Preventing Primary Sclerosing Cholangitis Recurrence After Liver Transplantation
NCT06905054
RECRUITING
PHASE2
Trial of High-dose Urso in Primary Sclerosing Cholangitis
NCT00059202
TERMINATED
PHASE2/PHASE3
Safety and Tolerability of Cilofexor in Participants With Primary Sclerosing Cholangitis (PSC) and Compensated Cirrhosis
NCT04060147
TERMINATED
PHASE1